Glycomics and Maternity

Glycans are complex sugars that decorate most proteins and lipids in living cells. Their shapes and linkages change in response to enzymes, hormones, diet and disease. During pregnancy these changes guide every key event: implantation, placental growth, vascular remodelling, immune tolerance, maternal metabolism and neonatal nutrition. Maternal blood shows a steady rise in galactosylated and sialylated immunoglobulin G, while acute-phase proteins and hormones acquire pregnancy-specific glyco-patterns. Placental cells express unique lectins such as galectin-13, galectin-9 and siglecs that read these sugar codes and fine-tune trophoblast invasion, spiral-artery dilation and defence against infection. Disruption of normal glycosylation contributes to pre-eclampsia, gestational diabetes, preterm birth, foetal growth restriction and other complications. Modern analytics now profile hundreds of glycans from a few microlitres of serum, map their spatial distribution in tissue at near-cellular resolution and predict novel structures with deep learning. These tools have uncovered candidate biomarkers, for example glycosylated fibronectin for early pre-eclampsia and poly-sialylated cervico-vaginal glycans for imminent pre-term birth. Therapeutic innovation is following fast: glyco-engineered antibodies, lectin blockers, small-molecule transferase inhibitors, exosome-based drug carriers and placenta-targeted lipid nanoparticles are in pre-clinical or early-phase testing. Safety evaluation must consider placental transfer, neonatal immunity and masking of maternal allo-antibodies. Standardised nomenclature, FAIR (Findable, Accessible, Interoperable, Reusable) data sharing and single-cell methods will accelerate progress. In summary, pregnancy offers a natural experiment in glycan biology, and functional glycomics now provides the tools to translate this knowledge into better diagnostics and treatments for mothers and babies.